DEVELOPMENT OF AN INNOVATIVE PROGNOSTIC APPROACH FOR PATIENTS WITH LUNG CANCER: FOCUS ON THE THERAPY — IMMUNEPHARMA SRL (Q2024033): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
||
| Property / financed by | |||
| Property / financed by: Directorate-General for Regional and Urban Policy / rank | |||
Revision as of 06:07, 2 November 2020
Project Q2024033 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF AN INNOVATIVE PROGNOSTIC APPROACH FOR PATIENTS WITH LUNG CANCER: FOCUS ON THE THERAPY — IMMUNEPHARMA SRL |
Project Q2024033 in Italy |
Statements
18,217.5 Euro
0 references
24,290.0 Euro
0 references
75.0 percent
0 references
7 November 2018
0 references
7 August 2019
0 references
IMMUNEPHARMA SRL
0 references
40°46'22.12"N, 14°47'57.98"E
0 references
OBIETTIVO Ê QUELLO DI UPGRADARE, TRAMITE IL CLIA TEST, I PRODOTTI DIAGNOSTICI *individuo* SOLO PER SCOPI DIAGNOSTICI, CON FUNZIONALITà CHE CONSENTANO LA PROGNOSI DEL PAZIENTE PRIMA E DOPO IL TRATTAMENTO FARMACOLOGICO, AL FINE DI PROMUOVERE IL SUCCESSO DELLA TERAPIA PERSONALIZZATA. LA IMPH DOVRà PROCEDERE ALLA IDENTIFICAZIONE DEL BIOMARKER, CASPASI-4, CHE HA UN ELEVATO POTERE DIAGNOSTICO, SECONDO I DATI SCIENTIFICI ACCERTATI DURANTE LE ATTIVITà DI RICERCA E SVILUPPO, A LIVELLO PLASMATICO IN PAZIENTI CHE A SEGUITO DI TRATTAMENTO CHIRURGICO O MENO, SARANNO SOTTOPOSTI A TERAPIA PERSONALIZZATA. SECONDO DATIPUBBLICATI, L'ANALISI BIOSTATISTICA IN RELAZIONE AI LIVELLI DEL MARCATORE DELLA IMPH HA EVIDENZIATO CHE LA SOPRAVVIVENZA MEDIANA DEI PAZIENTI CON LIVELLI ELEVATI DI CASPASI-4 ERA DI 0.92 ANNI RISPETTO A 3.02 ANNI, MEDIANA DI SOPRAVVIVENZA DEI PAZIENTI CON LIVELLI DI CASPASI-4 PIù BASSI. ALTRO DATO DI NOTEVOLE IMPORTANZA ÊCHE LA METà DI TALI PAZIENTI PRESENTAVA ANCORA LIVELLI ELEVAT (Italian)
0 references
Objective ÃO UPDATE, TRAMITE DIAGNOSTICI * individual * FOR DIAGNOSTIC PRODUCTS * ONLY FOR THE BENEFITS OF THE FIRST AND THE BENEFIT OF THE FIRST AND THE TEST, THE END OF THE PROPOSED BY THE TREATMENT, TO THE PROMOTION OF PEOPLE’S TERTIVATION. THE IMPH MUST CARRY OUT THE IDENTIFICATION OF BIOMARKER, CASPASI-4, WHICH HAS A HIGH DIAGNOSTIC POWER, ACCORDING TO THE SCIENTIFIC DATA ESTABLISHED DURING THE RESEARCH AND DEVELOPMENT ACTIVITIES, AT PLASMA LEVEL IN PATIENTS WHO AS A RESULT OF SURGICAL TREATMENT OR NOT, WILL BE SUBJECT TO PERSONALISED THERAPY. ACCORDING TO DATIPUBLCATI, THE BIOSTATISTICAL ANALYSIS IN RELATION TO THE LEVEL OF THE IMPH LEVEL SHOWED THAT THE MEDIAN SURVIVAL OF PATIENTS WITH HIGH LEVELS OF CASPASI-4 WAS 0.92 YEARS COMPARED TO 3.02 YEARS, MEDIAN SURVIVAL OF PATIENTS WITH LEVELS OF CASPASI-4 NETHERLANDS. EVEN THOUGH THE USE OF THESE PATIENTS WAS ALSO OF CONSIDERABLE IMPORTANCE? (English)
0 references
Identifiers
B43D18000310007
0 references